Holen Sie sich die Stockscreener-App
60.24
0.63%
-0.3533
Schlusskurs vom Vortag:
$60.59
Offen:
$60.6
24-Stunden-Volumen:
1.36M
Relative Volume:
0.44
Marktkapitalisierung:
$26.83B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
31.55
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
-4.60%
1M Leistung:
+6.06%
6M Leistung:
+31.35%
1J Leistung:
+64.96%
1-Tages-Spanne:
$59.31
$60.80
1-Wochen-Bereich:
$58.63
$64.38
52-Wochen-Spanne:
$34.63
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
60.25 | 26.98B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.08 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,007.57 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.75 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com India
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - Investing.com
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - pmg-ky3.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing - Seeking Alpha
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Strong Buy Ratings and Promising Growth in the Biotech Sector - DirectorsTalk Interviews
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal? - Sahm
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy" - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Commerzbank Aktiengesellschaft FI Invests $1.20 Million in Royalty Pharma PLC $RPRX - MarketBeat
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma - simplywall.st
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale - Stock Titan
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares - Investing.com South Africa
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated - Stock Titan
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan - Stock Titan
LYNWOOD PRICE CAPITAL MANAGEMENT LP's Royalty Pharma PLC(RPRX) Holding History - GuruFocus
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 10.49% Potential Upside - DirectorsTalk Interviews
S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX - MarketBeat
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years - Benzinga
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.49%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):